Papillary thyroid cancer accounts for approximately 90% Lymph Node Dissection in Papillary Thyroid Carcinoma
|
|
- Christal Taylor
- 8 years ago
- Views:
Transcription
1 Lymph Node Dissection in Papillary Thyroid Carcinoma Tracy-Ann S. Moo, MD, and Thomas J. Fahey III, MD The management of papillary thyroid carcinoma continues to evolve. Although the debate over the extent of thyroidectomy has largely faded, the role of elective neck dissection in the surgical management of papillary thyroid cancer has become a topic of contention. The current standard of care for patients with papillary thyroid cancer includes total thyroidectomy and a therapeutic lymph node dissection for patients presenting with clinically evident nodal disease. However, many surgeons advocate prophylactic central neck lymph node dissections in patients who present with no clinical or radiographic evidence of lymph node involvement. Proponents of prophylactic central compartment neck dissection argue that the incidence of central neck metastases is high and the sensitivity of preoperative ultrasound is low. Furthermore, central neck dissection advocates argue that clearing the central neck at the initial operation improves staging accuracy, assists in deciding on postoperative radioactive iodine treatment, and potentially avoids a higher-risk reoperative central neck dissection. Selective lateral neck dissections, as well as modified radical neck dissections, are accepted as necessary therapy in patients with clinically or radiographically positive lateral compartment disease. An essential component of any discussion on the extent of lymphadenectomy is whether patients derive any additional benefit from having a lymphadenectomy with total thyroidectomy and whether this can be done without significantly increasing the morbidity of the operation. Here we discuss the surgical options for approaching lymphadenectomy in patients presenting with papillary thyroid carcinoma. Semin Nucl Med 41: Elsevier Inc. All rights reserved. Papillary thyroid cancer accounts for approximately 90% of thyroid malignancies and continues to have an excellent prognosis, despite increasing in incidence during the past decade. 1 However, lymph node metastases are common and have been reported in up to 90% of patients with papillary thyroid carcinoma. 2,3 Many patients will present with subclinical nodal disease that is not detectable by ultrasonography or physical examination, and the sensitivity of preoperative ultrasound for central neck lymph node metastases is reported as low as 10%. 4 In the past, it was believed that there was no prognostic significance to lymph node involvement. However, more recent evidence demonstrates that the presence of lymph node metastases are associated with an increased risk of locoregional recurrence, and in older patients may be associated with a greater risk of death from thyroid cancer. 3,5-7 As such, the necessity for and extent of lymph node dissection have emerged as a controversial topic. New York Presbyterian Hospital, Cornell, New York, NY. Address reprint requests to Tracy-Ann Moo, MD, Weill Cornell Medical College, 525 East 68th Street F-2024, New York, NY trm9012@nyp.org. It is widely accepted that current surgical therapy for papillary thyroid carcinoma should include total thyroidectomy and therapeutic central neck dissection (CND) in those patients who present with clinically evident positive lymph nodes (Fig. 1). In these cases the level VI lymph nodes are removed. The dissection is carried out from the hyoid bone superiorly to the suprasternal notch inferiorly and is bordered laterally by the carotid sheaths and dorsally by the prevertebral fascia. This generally encompasses the area of initial spread of metastases through draining lymphatic channels of the thyroid. There have been reports of skip metastases that is direct metastases to the lateral neck however, this is probably rare and usually associated with carcinomas arising in the superior poles. 8 Prophylactic dissections of the central neck that is routine CND in patients without clinically evident signs of nodal disease by physical examination or preoperative imaging is more controversial because CND is not without morbidity. Within this compartment lie the parathyroid glands and the recurrent laryngeal nerves, and the added dissection potentially increases the possibility of hypoparathyroidism or recurrent nerve injury when performing a total thyroidectomy with CND vs. thyroidectomy alone. 9, /11/$-see front matter 2011 Elsevier Inc. All rights reserved. doi: /j.semnuclmed
2 LN dissection in papillary thyroid carcinoma 85 In patients who present with clinically evident disease, the standard of care is to perform a therapeutic neck dissection, which entails the systematic removal of the lymph nodes in the central compartment (level VI). It is thought that this reduces rates of lymph node recurrence as it has been shown that a large number of nodal recurrences occur in the central neck. 12,13 It is widely accepted that a berry-picking approach to clinically positive lymph nodes is not an acceptable approach and results in high rates of locoregional recurrence. 14,15 Davidson et al, 15 in a review of one institution s experience, examined 183 patients treated for papillary thyroid carcinoma with thyroidectomy and various methods of lymphadenectomy. In this study population there was a recurrence rate of 33%, and the authors found that the greatest rates of recurrence were among those patients who had had a berry-picking approach to cervical lymphadenectomy. In addition, we now know that routine CND can be performed safely with low rates of permanent hypoparathyroidism as well as recurrent laryngeal nerve injury. 12,16 Although the authors of previous studies quoted high rates of hypoparathyroidism as well as recurrent laryngeal nerve injury, more recent data has demonstrated that central neck lymph node dissections can be done with minimal morbidity. Grant et al examined a series of 420 patients with papillary thyroid carcinoma who underwent thyroidectomy with CND and reported a 1.2% incidence of hypoparathyroidism and only 1 case of recurrent laryngeal nerve injury. 10,12 Figure 1 Central neck lymph node dissection area. The surgical management of papillary thyroid carcinoma now focuses on the prevention of locoregional recurrence as well as on long-term survival. Proponents of prophylactic central compartment dissection argue that in addition to potentially avoiding the morbidity of a reoperation, prophylactic dissections provide more accurate staging which facilitates decisions regarding postoperative radioactive iodine treatment, as well as long term follow-up with thyroglobulin levels. Recent American Thyroid Association guidelines advocate the consideration of prophylactic central neck lymph node dissection in patients with papillary thyroid carcinoma and more so in patients with T3 or T4 primary lesions. 11 Therapeutic Central Neck Lymph Node Dissection Prophylactic Central Neck Lymph Node Dissection Although there are no prospective randomized controlled studies demonstrating the efficacy of prophylactic central neck lymph node dissection, in many centers it is performed routinely. The rationale is that it reduces the morbidity associated with a potential reoperation, reduces the risk of central neck lymph node recurrence, provides more accurate information for staging, and facilitates postoperative radioactive iodine administration as well as long term follow-up. At the heart of the controversy is the fact that central neck lymph node metastases are common in papillary thyroid cancer. In tumors that are 1 cm, central neck lymph node metastases are found in 40 to almost 90% of cases. Even in papillary microcarcinoma the rate of lymph node metastases has been reported in 25%-45% of cases. 17,18 Bonnet et al 19 recently examined the importance of the status of the central neck lymph nodes to postoperative management, even in small PTC. Bonnet retrospectively reviewed 115 patients with papillary thyroid carcinoma and a tumor size 2 cm without ultrasonographic evidence of lymph node metastases preoperatively who underwent prophylactic CND. Information provided by knowing the pathologic stage of the central neck lymph nodes changed the staging for 30% of patients initially staged as T1N0, and ultimately modified the indication for radioactive iodine ablation in these patients. Opponents of prophylactic CND argue that the presence of positive lymph nodes does not affect prognosis and survival in papillary thyroid carcinoma For example, Shaha et al 21 performed a retrospective review of 810 patients looking at prognostic factors, and found that while female sex, young age, extracapsular extension and low grade histology were favorable prognosticators, the presence of positive lymph nodes had no effect on prognosis. Although the authors of many older studies demonstrated that survival was not affected by the presence of metastatic lymph nodes, nodal disease has been associated with a significantly increased recurrence in more recent studies. Hughes et al 23 performed a matched-pair analysis of 100 patients with previously untreated papillary thyroid carcinoma with and without lymph node involvement. In this study he looked at the significance
3 86 T.-A.S. Moo and T.J. Fahey of nodal disease in patients with otherwise equivalent prognostic factors and found that while there was no difference in survival, patients with nodal involvement did have a higher rate of recurrence, and in patients over 45 years this difference was statistically significant. Additional studies also support the findings of Hughes, et al that lymph node metastasis increases the rate of locoregional recurrence. 5,6,15,24 Furthermore, recent evidence from examination of a large database indicates that lymph node metastasis can be associated with a negative impact on survival. Lundgren, et al performed a nested-case control study and looked at 5123 patients diagnosed with differentiated thyroid cancer. The authors report that patients with lymph node metastases had a significantly higher mortality than those without. 6 There is also emerging evidence that prophylactic CND may lead to reduced central neck recurrence. Grant et al 12 reviewed 420 patients who had undergone an optimized surgical approach to papillary thyroid carcinoma. These patients all had preoperative ultrasounds to specifically assess for central and lateral compartment lymph node involvement and then underwent bilateral thyroidectomy, routine central neck lymph node dissection and selective lateral neck dissection (compartments III, IV, and V) in those patients with positive lymph nodes detected by ultrasonography or palpation preoperatively. The authors report a locoregional recurrence rate of only 5% in the previously operated field. Similarly, data from our own institution corroborates these findings. We performed a retrospective review of 81 patients presenting with papillary thyroid cancer without clinical evidence of nodal disease. Thirty-seven of these patients underwent thyroidectomy alone whereas 45 underwent thyroidectomy with prophylactic lymph node dissection. Our results demonstrated a 4.4% locoregional recurrence rate in patients who had a prophylactic CND compared with 16.7% recurrence rate for patients undergoing thyroidectomy alone. 16 These data, however, have yet to be supported by prospective trials. Operative morbidity is a major concern in proposing more widespread adoption of routine prophylactic neck dissection. Though in experienced hands CND has low rates of both permanent hypoparathyroidism and permanent recurrent laryngeal nerve injury, there are clearly higher rates of temporary hypoparathyroidism and recurrent laryngeal nerve injury. In our experience with patients undergoing total thyroidectomy with prophylactic CND vs. total thyroidectomy alone, there was a significantly higher rate of temporary hypoparathyroidism in those patients who had CND, 31% versus 5% (P 0.001; Fig. 2). Because most thyroid surgery in the United States is performed by surgeons who do fewer than 10 thyroidectomies per year, 25 there is considerable concern that in the hands of less-experienced surgeons, the incidence of permanent hypoparathyroidism or injury to the recurrent laryngeal nerves would increase substantially. Nevertheless, proponents of prophylactic CND point to the greater risks of hypoparathyroidism and recurrent laryngeal nerve injury in reoperative central neck surgery as a justification for attempting to clear central neck disease at the initial operation Figure 2 Complication rates in patients undergoing total thyroidectomy with and without CND. In an effort to minimize the potential morbidity of a CND, there have been studies looking into the efficacy of a CND carried out only on the side of the tumor. Data from our institution and others demonstrate that tumors 1 cm rarely metastasize to the contralateral central neck lymph nodes. We performed a prospective study of central neck lymph dissection in 116 patients. In patients with tumors 1 cm compared with those with tumors 1 cm, there was 0% versus 31% (P 0.02) incidence of bilateral lymph node metastasis. 18 In the subset of patients with tumors 1 cm, an ipsilateral CND may be a viable alternative and should provide the additional information gained from staging the central neck lymph nodes, while at the same time reducing the additional risk of CND. Selective Lateral Neck and Modified Radical Neck Dissection A selective lateral neck dissection includes the lymph nodes of levels III, IV, and V. However, this dissection usually does not extend posterior to the sternocleidomastoid muscle and to the border of the trapezius. It is generally agreed that this should be performed in the presence of clinically apparent disease and in conjunction with a central compartment dissection (Fig. 3). Patients who present with clinically positive lateral lymph nodes by examination or ultrasound are also likely to have central compartment disease. Pereira, et al found that patients with positive lateral neck lymph nodes had at least 6 positive central neck nodes at lymphadenectomy. 29 There appears to be no role for prophylactic lateral neck dissections as the lateral compartment is not usually entered during thyroidectomy and can be operated on without greater morbidity if necessary in the future. Vergez et al retrospectively looked at 90 patients who had undergone prophylactic central and lateral neck dissection at the time of thyroidectomy to determine pattern of lymph node involvement. They found that 62/90 patients who had lateral neck dissection had no lymph node involvement, and all patients with positive lateral neck lymph nodes also had positive cen-
4 LN dissection in papillary thyroid carcinoma 87 Figure 3 Approach to lymph node dissection in papillary thyroid carcinoma. PTC, papillary thyroid carcinoma; LNM, lymph node metastasis; CND, central neck dissection; MRND, modified radical neck dissection. (Color version of figure is available online.) tral neck lymph nodes. There was no incidence of skip metastases. They concluded that prophylactic lateral neck dissections are not necessary as the lateral neck can be operated on without increased morbidity after thyroidectomy should metastases subsequently be detected. Furthermore, unlike the central neck, the sensitivity of ultrasound for detecting positive lymph nodes in the lateral neck is quite high. 30 Modified radical neck dissection usually includes a dissection of lymph nodes in compartments II through V. In contrast to a radical neck dissection, the sternocleidomastoid muscle, spinal accessory nerve and internal jugular vein are preserved. Even so, the morbidity of this operation is high, with rates of shoulder dysfunction secondary to spinal accessory nerve injury reported in up to 30%. 31 Although some centers advocate full modified radical neck dissection when there is any evidence for involvement of the lateral neck lymph nodes, there is evidence to suggest that metastases to compartment II are rare in the absence of clinical disease at level II. 32 Caron et al reviewed 104 pt who underwent modified radical neck dissection, including compartments I, II, and V, and found no statistically significant difference in recurrence at level II when the compartment had been dissected vs. when it had not been dissected. They concluded, on the basis of this relatively small sample size, that this compartment should only be dissected when there is clinically evident disease, when there are signs of aggressive disease or when there is extensive nodal disease in compartment III. 33 Future controversy is likely to revolve around the use of lateral compartment neck dissections in patients with subclinical lymph node metastases in the lateral neck. This population of patients is likely to increase in size as preoperative lateral neck ultrasonography becomes more widely employed in the initial evaluation of patients with papillary thyroid cancer. Conclusions Decisions regarding lymphadenectomy in papillary thyroid carcinoma remain controversial. This is especially the case in patients presenting with no clinical evidence for lymph node metastases by physical examination or preoperative ultrasound. Therapeutic CNDs are preformed routinely with minimal morbidity in the hands of experienced surgeons. Although there is a current paucity of data demonstrating a clear decrease in recurrence for prophylactic CND, it should be considered in all patients presenting for treatment of papillary thyroid carcinoma. Perhaps an ipsilateral CND may be sufficient in patients with papillary microcarcinomas. The addition of central neck dissection to thyroidectomy is beneficial for achieving completeness of disease resection and can provide important information regarding tumor staging, thus facilitating postoperative management and long-term follow up. Selective lateral neck dissection and modified radical neck dissections should be performed when there is clinical evidence of nodal disease in the lateral neck compartments. References 1. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al: Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: , Rotstein L: The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol 99: , Machens A, Hinze R, Thomusch O, et al: Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22-28, Ito Y, Tomoda C, Uruno T, et al: Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 30:91-99, Scheumann GF, Gimm O, Wegener G, et al: Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18: , 1994; discussion: Lundgren CI, Hall P, Dickman PW, et al: Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106: , Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: , Roh JL, Park JY, Rha KS, et al: Is central neck dissection necessary for the treatment of lateral cervical nodal recurrence of papillary thyroid carcinoma? Head Neck 29: , Dionigi G, Dionigi R, Bartalena L, et al: Surgery of lymph nodes in papillary thyroid cancer. Expert Rev Anticancer Ther 6: , Roh JL, Kim JM, Park CI: Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol 15: , Cooper DS, Doherty GM, Haugen BR, et al: Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroidology 19: , Grant CS, Stulak JM, Thompson GB, et al: Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during World J Surg 34: , Frasoldati A, Pesenti M, Gallo M, et al: Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97:90-96, Musacchio MJ, Kim AW, Vijungco JD, et al: Greater local recurrence occurs with berry picking than neck dissection in thyroid cancer. Am Surg 69: , 2003; discussion: Davidson HC, Park BJ, Johnson JT: Papillary thyroid cancer: controversies in the management of neck metastasis. Laryngoscope 118: , Moo TA, McGill J, Allendorf J, et al: Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg 34: , Arora N, Turbendian HK, Kato MA, et al: Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroidology 19: , 2009
5 88 T.-A.S. Moo and T.J. Fahey 18. Moo TA, Umunna B, Kato M, et al: Ipsilateral versus bilateral Central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg 250: , Bonnet S, Hartl D, Leboulleux S, et al: Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94: , Sato N, Oyamatsu M, Koyama Y, et al: Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J Surg Oncol 69: , Shaha AR, Shah JP, Loree TR: Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 3: , Shah JP, Loree TR, Dharker D, et al: Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164: , Hughes CJ, Shaha AR, Shah JP, et al: Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 18: , Soyluk O, Selcukbiricik F, Erbil Y, et al: Prognostic factors in patients with papillary thyroid carcinoma. J Endocrinol Invest 31: , Sosa JA, Bowman HM, Tielsch JM, et al: The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228: , Pattou F, Combemale F, Fabre S, et al: Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg 22: , Kim MK, Mandel SH, Baloch Z, et al: Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg 130: , Chao TC, Jeng LB, Lin JD, et al: Reoperative thyroid surgery. World J Surg 21: , Pereira JA, Jimeno J, Miquel J, et al: Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138: , 2005; discussion: Kouvaraki MA, Shapiro SE, Fornage BD, et al: Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134: , 2003; discussion: Cappiello J, Piazza C, Giudice M, et al: Shoulder disability after different selective neck dissections (levels II IV versus levels II-V): a comparative study. Laryngoscope 115: , Lee J, Sung TY, Nam KH, et al: Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients? World J Surg 32: , Caron NR, Tan YY, Ogilvie JB, et al: Selective modified radical neck dissection for papillary thyroid cancer-is level I, II, and V dissection always necessary? World J Surg 30: , 2006
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationLatest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma
Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationRecurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve,
Recurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve, Larynx, Trachea, & Esophageal Management Robert C. Wang,
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationThyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD
Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationHemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma
1412 Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma XIAOLONG LI 1*, CUI ZHAO 1*, DANDAN HU 1, YANG YU 1, JIN GAO 2, WENCHUAN
More informationAdvances in Differentiated Thyroid Cancer
Advances in Differentiated Thyroid Cancer Steven A. De Jong, M.D., FACS, FACE Professor and Vice Chair Clinical Affairs Department of Surgery Loyola University Medical Center Thyroid Cancer classification
More informationReoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer
Reoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer Sara I. Pai, MD, PhD a,b, Ralph P. Tufano, MD a, * KEYWORDS Recurrent/persistent papillary thyroid cancer Well-differentiated thyroid
More informationFollowup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm
Followup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm Elizabeth A Mittendorf, MD, Xuemei Wang, MS, Nancy D Perrier, MD, Ashleigh M Francis, BSPH, Beth S Edeiken, MD, Suzanne
More informationLocoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
More informationIV. DEFINITION OF LYMPH NODE GROUPS (FIGURE 1) Level IA: Submental Group
IV. DEFINITION OF LYMPH NODE GROUPS (FIGURE 1) Fig. 1 The level system is used for describing the location of lymph nodes in the neck: Level I, submental and submandibular group; Level II, upper jugular
More informationThyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules)
Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules) Jeffrey S. Freeman, D.O., F.A.C.O.I. Chairman, Division of Endocrinology and Metabolism Philadelphia College
More informationPreventable reoperations for persistent and recurrent papillary thyroid carcinoma
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma Maria A. Kouvaraki, MD, PhD, Jeffrey E. Lee, MD, Suzanne E. Shapiro, MS, Steven I. Sherman, MD, and Douglas B. Evans, MD,
More informationWell-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival
Singapore Med J 2002 Vol 43(9) : 457-462 O r i g i n a l A r t i c l e Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival L H Y Lim, K C Soo, Y K Chong, F Gao, G S Hong,
More informationORIGINAL ARTICLE. Results of Salvage Treatment of the Neck in Patients With Oral Cancer
Results of Salvage Treatment of the in Patients With Oral Cancer Luiz P. Kowalski, MD, PhD ORIGINAL ARTICLE Background: About 50% of the patients with neck recurrences after the treatment of oral squamous
More informationThyroid and Adrenal Gland
Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More information0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Copyright 1997 by The Endocrine Society
0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Pathological Tumor-Node-Metastasis (ptnm) Staging for Papillary
More informationStaging Head and Neck Cancers Transitioning to the Seventh Edition of The AJCC Cancer Staging Manual
Staging Head and Neck Cancers Transitioning to the Seventh Edition of The AJCC Cancer Staging Manual Jatin P. Shah, MD, PhD (Hon) Memorial Sloan-Kettering Cancer Center New York, New York The American
More informationIl percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare
Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
More informationPrediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma
Clinical Endocrinology (2014) 81, 282 288 doi: 10.1111/cen.12417 ORIGINAL ARTICLE Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma Yinlong Yang*,, Chengze Chen,
More informationRegional Lymph Node Metastasis in Papillary Thyroid Cancer
REVIEW ARTICLE ISSN: 2005-162X Clin Exp Thyroidol 2014 November 7(2): 129-135 http://dx.doi.org/10.11106/cet.2014.7.2.129 Regional Lymph Node Metastasis in Papillary Thyroid Cancer Jae Hyun Park, Kang
More informationImage. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
More informationClinicopathological features of recurrent papillary thyroid cancer
Zhu et al. Diagnostic Pathology (2015) 10:96 DOI 10.1186/s13000-015-0346-5 RESEARCH Open Access Clinicopathological features of recurrent papillary thyroid cancer Jian Zhu 1, Xinli Wang 2, Xiaoxuan Zhang
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More information13 Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer
13 Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer John C. Watkinson Introduction The majority of patients with differentiated thyroid cancer have papillary carcinoma and most are treated
More informationShould All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases
PAPERS OF THE 131ST ASA ANNUAL MEETING Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases Xiao-Min Yu, MD, PhD, Yin Wan, MS, Rebecca S. Sippel, MD, FACS,
More informationTNM Staging of Head and Neck Cancer and Neck Dissection Classification
QUICK REFERENCE GUIDE TO TNM Staging of Head and Neck Cancer and Neck Dissection Classification Fourth Edition 2014 All materials in this ebook are copyrighted by the American Academy of Otolaryngology
More informationThyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010
Thyroid Cancer Diagnosis and Management Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010 DISCLOSURE NOTHING TO DISCLOSE in regard to financial conflict
More informationHow to treat early gastric cancer. Surgery
How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationCurrent Treatment of Papillary Thyroid Microcarcinoma
Advances in Surgery 46 (2012) 191 203 ADVANCES IN SURGERY Current Treatment of Papillary Thyroid Microcarcinoma Xiao-Min Yu, MD, PhD a, Ricardo Lloyd, MD, PhD b, Herbert Chen, MD c, * a Department of Surgery,
More informationThe American Joint Committee on Cancer (AJCC)
THY-2012-0043-ver9-Randolph_3P.3d 10/13/12 6:42am Page 1 THYROID Volume 22, Number 11, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/thy.2012.0043 THYROID CANCER AND NODULES The Prognostic Significance of
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationSurvival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationManagement of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital
Review Management of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital Pei-Wen Wang Abstract Background. Most thyroid cancers
More informationCervical lymph node dissection in papillary thyroid cancer: Current trends, persisting controversies, and unclarified uncertainties
Surgical Oncology (2010) 19, e57ee70 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/suronc REVIEW Cervical lymph node dissection in papillary thyroid cancer: Current trends,
More informationOriginal Investigation
Research Original Investigation Lack of Association of BRAF Mutation With Negative Prognostic Indicators in Papillary Thyroid Carcinoma The University of California, San Francisco, Experience Christopher
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationInfluence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma
ORIGINAL ARTICLE Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma Jasna Mihailovic, MD, PhD,*Þ Ljubomir Stefanovic, MD, PhD,* and Ranka
More informationRESEARCH COMMUNICATION
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.4.1267 BRAF Mutation is Predictive of Occult Contralateral Carcinoma in Papillary Thyroid Microcarcinoma Cases RESEARCH COMMUNICATION Preoperative BRAF Mutation
More informationIntensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer
Thyroid Science 5(1):CLS1-8, 2010 www.thyroidscience.com Clinical and Laboratory Studies Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer 1 2 5 Aruna Turaka, MD, Tianyu Li, MS, Jian Q. Yu,
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationBreast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
More informationControlling recurrent papillary thyroid carcinoma in the neck by ultrasonographyguided
Eur Radiol (2008) 18: 835 842 DOI 10.1007/s00330-007-0809-5 HEAD AND NECK Byung Moon Kim Min Jung Kim Eun-Kyung Kim Sung Il Park Cheong Soo Park Woong Youn Chung Controlling recurrent papillary thyroid
More information<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012
More information
VC 2012 The American Laryngological, Rhinological and Otological Society, Inc. TRIOLOGICAL SOCIETY CANDIDATE THESIS
The Laryngoscope VC 2012 The American Laryngological, Rhinological and Otological Society, Inc. TRIOLOGICAL SOCIETY CANDIDATE THESIS Reoperative Central Compartment Dissection for Patients With Recurrent/Persistent
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationA Practical Guide to Advances in Staging and Treatment of NSCLC
A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationPapillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine
Original Article 663 Papillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine Sheng-Fong Kuo, MD; Szu-Tah Chen, MD, PhD; Pan-Fu Kao 1, MD; Yu-Chen Chang 1, MD; Shuo-Chi Chou,
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationI Radiotherapy of Pediatric Thyroid Cancer
131 I Radiotherapy of Pediatric Thyroid Cancer Steven Waguespack, MD Associate Professor Dept of Endocrine Neoplasia and Hormonal Disorders Department of Pediatrics Patient Care University of Texas M.D.
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationMEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15
MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationConflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.
Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates Jeffrey F. Krane, MD PhD Associate Professor of Pathology Harvard Medical School Chief, Head and Neck Pathology Service Associate Director,
More informationBRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
More informationValidation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationThe Relationship Between Lymphocytic Infiltration in the Thyroid Gland and Tumor Recurrence in Papillary Thyroid Carcinoma
Turkish Journal of Endocrinology and Metabolism, (1999) 3 : 113-117 ORIGINAL ARTICLE The Relationship Between Lymphocytic Infiltration in the Thyroid Gland and Tumor Recurrence in Papillary Thyroid Carcinoma
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationSurgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
More informationThyroid Surgery at Massachusetts General Hospital Frequently Asked Questions
Thyroid Surgery at Massachusetts General Hospital Frequently Asked Questions Q: What is the thyroid gland? A: The thyroid is a butterfly-shaped gland located in the front of the neck. It is one of the
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationManagement Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
THYROID Volume 16, Number 2, 2006 American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Taskforce*
More informationPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
More informationCorporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationThe epidemic of thyroid cancer and its evolving management: Is less more?
The epidemic of thyroid cancer and its evolving management: Is less more? Julie Ann Sosa, MD MA FACS Professor of Surgery and Medicine Chief, Section of Endocrine Surgery, and Leader, Endocrine Neoplasia
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More informationBridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS
Bridging Techniques What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS Associate Professor of Surgery Assistant Program Director, General Surgery Residency Disclosures
More informationThe Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
More informationThe incidence of thyroid cancer has increased exponentially over
FEATURE THYROID Papillary thyroid cancer: the most common endocrine malignancy JAMES C. LEE FRACS STANLEY B. SIDHU FRACS, PhD Papillary thyroid cancer has an excellent prognosis and over 90% of affected
More informationBAISHIDENG PUBLISHING GROUP INC
Reviewer s code: 01714224 Reviewer s country: Italy Date reviewed: 2015-01-30 20:36 [ Y] Grade A: Priority publishing [ ] Accept [ ] Grade C: Good [ Y] Grade D: Fair language [ Y] Major revision The article
More informationPANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationAdjuvant Radioactive Iodine Use Among Differentiated Thyroid Cancer Patients in the Military Health System
MILITARY MEDICINE, 179, 9:1043, 2014 Adjuvant Radioactive Iodine Use Among Differentiated Thyroid Cancer Patients in the Military Health System Abegail A. Gill, MPH*; Lindsey Enewold, PhD*; Shelia H. Zahm,
More informationManagement of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed
Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed Medical Grand Rounds December 10,2015 Christine Signore, MD ECNU Learning Objectives Discuss the epidemiology
More informationTreating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationClinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More information